-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
China's self-developed dual-carrier 13-valent pneumonia vaccine was officially launched in Guangzhou on the 4th
.
It is reported that the vaccine uses two carrier proteins (tetanus toxoid/diphtheria toxoid) combined with pneumococcal capsular polysaccharide, which is a dual-carrier 13-valent pneumococcal polysaccharide conjugate vaccine independently developed by China
.
.
It is reported that the vaccine uses two carrier proteins (tetanus toxoid/diphtheria toxoid) combined with pneumococcal capsular polysaccharide, which is a dual-carrier 13-valent pneumococcal polysaccharide conjugate vaccine independently developed by China
.
In recent years, the drug resistance of pneumococcus has continued to increase.
In 2017, pneumococcus was included in the list of " Deadly Drug-resistant Bacteria that Seriously Threaten Human Health " by the World Health Organization
.
According to Zheng Huizhen, chief physician of the Guangdong Provincial Center for Disease Control and Prevention, children under 5 years of age have not yet fully developed immune function and are always facing a huge risk of pneumococcal invasion
.
Once infected with a pneumococcal disease, it is extremely likely to cause severe sequelae such as mental retardation and paralysis, in addition to meningitis and otitis media
.
In 2017, pneumococcus was included in the list of " Deadly Drug-resistant Bacteria that Seriously Threaten Human Health " by the World Health Organization
.
According to Zheng Huizhen, chief physician of the Guangdong Provincial Center for Disease Control and Prevention, children under 5 years of age have not yet fully developed immune function and are always facing a huge risk of pneumococcal invasion
.
Once infected with a pneumococcal disease, it is extremely likely to cause severe sequelae such as mental retardation and paralysis, in addition to meningitis and otitis media
.
Zheng Huizhen said: "The 13-valent pneumonia vaccine can protect children from the 13 most common and harmful pneumococcal serotypes, and help children build a protective barrier, which is of great significance to the healthy growth of children
.
"
.
"
Zheng Jingshan, vice president of the Guangdong Preventive Medicine Association, introduced that the use of dual carriers can prevent a single carrier protein from competing with helper T cells and inhibiting the polysaccharide immune response
.
The Phase III clinical trial data of Kangtai Bio's 13-valent pneumonia vaccine shows that the vaccine has mild adverse reactions .
Kangtai Bio's 13-valent pneumonia vaccine has good effects on infants and children from 6 weeks to 5 years old (before the 6th birthday).
Compared with the past Similar vaccines have relaxed the time limit for vaccination
.
.
The Phase III clinical trial data of Kangtai Bio's 13-valent pneumonia vaccine shows that the vaccine has mild adverse reactions .
Kangtai Bio's 13-valent pneumonia vaccine has good effects on infants and children from 6 weeks to 5 years old (before the 6th birthday).
Compared with the past Similar vaccines have relaxed the time limit for vaccination
.
Guangdong Provincial Maternal and Child Health Hospital pediatric emergency department director Zhao Changan said, as children vaccinated pneumonia vaccine is the best protection of children from harm is
.
"Especially in the winter, children enclosed areas such as children's park-intensive, higher risk of cross infection
.
Vaccination early, preventive, undoubtedly the most economical and the most safe and effective protection
.
" (End)
.
"Especially in the winter, children enclosed areas such as children's park-intensive, higher risk of cross infection
.
Vaccination early, preventive, undoubtedly the most economical and the most safe and effective protection
.
" (End)
China's self-developed dual-carrier 13-valent pneumonia vaccine was officially launched in Guangzhou on the 4th
.
It is reported that the vaccine uses two carrier proteins (tetanus toxoid/diphtheria toxoid) combined with pneumococcal capsular polysaccharide, which is a dual-carrier 13-valent pneumococcal polysaccharide conjugate vaccine independently developed by China
.
.
It is reported that the vaccine uses two carrier proteins (tetanus toxoid/diphtheria toxoid) combined with pneumococcal capsular polysaccharide, which is a dual-carrier 13-valent pneumococcal polysaccharide conjugate vaccine independently developed by China
.
In recent years, the drug resistance of pneumococcus has continued to increase.
In 2017, pneumococcus was included in the list of " Deadly Drug-resistant Bacteria that Seriously Threaten Human Health " by the World Health Organization
.
According to Zheng Huizhen, chief physician of the Guangdong Provincial Center for Disease Control and Prevention, children under 5 years of age have not yet fully developed immune function and are always facing a huge risk of pneumococcal invasion
.
Once infected with a pneumococcal disease, it is extremely likely to cause severe sequelae such as mental retardation and paralysis, in addition to meningitis and otitis media
.
In 2017, pneumococcus was included in the list of " Deadly Drug-resistant Bacteria that Seriously Threaten Human Health " by the World Health Organization
.
According to Zheng Huizhen, chief physician of the Guangdong Provincial Center for Disease Control and Prevention, children under 5 years of age have not yet fully developed immune function and are always facing a huge risk of pneumococcal invasion
.
Once infected with a pneumococcal disease, it is extremely likely to cause severe sequelae such as mental retardation and paralysis, in addition to meningitis and otitis media
.
Zheng Huizhen said: "The 13-valent pneumonia vaccine can protect children from the 13 most common and harmful pneumococcal serotypes, and help children build a protective barrier, which is of great significance to the healthy growth of children
.
"
.
"
Zheng Jingshan, vice president of the Guangdong Preventive Medicine Association, introduced that the use of dual carriers can prevent a single carrier protein from competing with helper T cells and inhibiting the polysaccharide immune response
.
The Phase III clinical trial data of Kangtai Bio's 13-valent pneumonia vaccine shows that the vaccine has mild adverse reactions .
Kangtai Bio's 13-valent pneumonia vaccine has good effects on infants and children from 6 weeks to 5 years old (before the 6th birthday).
Compared with the past Similar vaccines have relaxed the time limit for vaccination
.
.
The Phase III clinical trial data of Kangtai Bio's 13-valent pneumonia vaccine shows that the vaccine has mild adverse reactions .
Kangtai Bio's 13-valent pneumonia vaccine has good effects on infants and children from 6 weeks to 5 years old (before the 6th birthday).
Compared with the past Similar vaccines have relaxed the time limit for vaccination
.
Guangdong Provincial Maternal and Child Health Hospital pediatric emergency department director Zhao Changan said, as children vaccinated pneumonia vaccine is the best protection of children from harm is
.
"Especially in the winter, children enclosed areas such as children's park-intensive, higher risk of cross infection
.
Vaccination early, preventive, undoubtedly the most economical and the most safe and effective protection
.
" (End)
.
"Especially in the winter, children enclosed areas such as children's park-intensive, higher risk of cross infection
.
Vaccination early, preventive, undoubtedly the most economical and the most safe and effective protection
.
" (End)
China's self-developed dual-carrier 13-valent pneumonia vaccine was officially launched in Guangzhou on the 4th
.
It is reported that the vaccine uses two carrier proteins (tetanus toxoid/diphtheria toxoid) combined with pneumococcal capsular polysaccharide, which is a dual-carrier 13-valent pneumococcal polysaccharide conjugate vaccine independently developed by China
.
.
It is reported that the vaccine uses two carrier proteins (tetanus toxoid/diphtheria toxoid) combined with pneumococcal capsular polysaccharide, which is a dual-carrier 13-valent pneumococcal polysaccharide conjugate vaccine independently developed by China
.
In recent years, the drug resistance of pneumococcus has continued to increase.
In 2017, pneumococcus was included in the list of " Deadly Drug-resistant Bacteria that Seriously Threaten Human Health " by the World Health Organization
.
According to Zheng Huizhen, chief physician of the Guangdong Provincial Center for Disease Control and Prevention, children under 5 years of age have not yet fully developed immune function and are always facing a huge risk of pneumococcal invasion
.
Once infected with a pneumococcal disease, it is extremely likely to cause severe sequelae such as mental retardation and paralysis, in addition to meningitis and otitis media
.
Healthy, healthy, healthyIn 2017, pneumococcus was included in the list of " Deadly Drug-resistant Bacteria that Seriously Threaten Human Health " by the World Health Organization
.
According to Zheng Huizhen, chief physician of the Guangdong Provincial Center for Disease Control and Prevention, children under 5 years of age have not yet fully developed immune function and are always facing a huge risk of pneumococcal invasion
.
Once infected with a pneumococcal disease, it is extremely likely to cause severe sequelae such as mental retardation and paralysis, in addition to meningitis and otitis media
.
Zheng Huizhen said: "The 13-valent pneumonia vaccine can protect children from the 13 most common and harmful pneumococcal serotypes, and help children build a protective barrier, which is of great significance to the healthy growth of children
.
"
.
"
Zheng Jingshan, vice president of the Guangdong Preventive Medicine Association, introduced that the use of dual carriers can prevent a single carrier protein from competing with helper T cells and inhibiting the polysaccharide immune response
.
The Phase III clinical trial data of Kangtai Bio's 13-valent pneumonia vaccine shows that the vaccine has mild adverse reactions .
Kangtai Bio's 13-valent pneumonia vaccine has good effects on infants and children from 6 weeks to 5 years old (before the 6th birthday).
Compared with the past Similar vaccines have relaxed the time limit for vaccination
.
Adverse reactions adverse reactions adverse reactions.
The Phase III clinical trial data of Kangtai Bio's 13-valent pneumonia vaccine shows that the vaccine has mild adverse reactions .
Kangtai Bio's 13-valent pneumonia vaccine has good effects on infants and children from 6 weeks to 5 years old (before the 6th birthday).
Compared with the past Similar vaccines have relaxed the time limit for vaccination
.
Guangdong Provincial Maternal and Child Health Hospital pediatric emergency department director Zhao Changan said, as children vaccinated pneumonia vaccine is the best protection of children from harm is
.
"Especially in the winter, children enclosed areas such as children's park-intensive, higher risk of cross infection
.
Vaccination early, preventive, undoubtedly the most economical and the most safe and effective protection
.
" (End)
Health Care Health Children Children Children Children Children Children .
"Especially in the winter, children enclosed areas such as children's park-intensive, higher risk of cross infection
.
Vaccination early, preventive, undoubtedly the most economical and the most safe and effective protection
.
" (End)
